tradingkey.logo

Stevanato Group SpA

STVN

26.913USD

-0.017-0.06%
Market hours ETQuotes delayed by 15 min
7.34BMarket Cap
54.58P/E TTM

Stevanato Group SpA

26.913

-0.017-0.06%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
3 / 207
Overall Ranking
32 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Buy
Current Rating
29.103
Target Price
+6.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.02% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 12.27%.
Overvalued
The company’s latest PE is 54.52, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.23M shares, decreasing 21.42% quarter-over-quarter.
Held by Ron Baron
Star Investor Ron Baron holds 1.89M shares of this stock.

Financial Health

Currency: USD Updated2025-09-17

The company's current financial score is 8.55, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 237.60M, representing a year-over-year decrease of 1.94%, while its net profit experienced a year-over-year decrease of 30.90%.

Score

Industry at a Glance

Previous score
8.55
Change
0

Financials

7.39

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

8.62

Operational Efficiency

9.24

Growth Potential

9.93

Shareholder Returns

7.54

Company Valuation

Currency: USD Updated2025-09-17

The company’s current valuation score is 3.91, which is higher than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is 54.52, which is -5.45% below the recent high of 51.55 and 18.88% above the recent low of 44.23.

Score

Industry at a Glance

Previous score
4.68
Change
-0.77

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-17

The company’s current earnings forecast score is 8.36, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Stevanato Group SpA is 28.00, with a high of 37.00 and a low of 23.00.

Score

Industry at a Glance

Previous score
8.36
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts
Buy
Current Rating
29.103
Target Price
+8.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Stevanato Group SpA
STVN
11
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-17

The company’s current price momentum score is 9.38, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 29.22 and the support level at 23.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.32
Change
0.06

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.814
Buy
RSI(14)
63.421
Neutral
STOCH(KDJ)(9,3,3)
85.278
Overbought
ATR(14)
1.440
High Vlolatility
CCI(14)
85.194
Neutral
Williams %R
13.800
Overbought
TRIX(12,20)
0.544
Sell
StochRSI(14)
43.192
Neutral
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
26.736
Buy
MA10
25.879
Buy
MA20
24.281
Buy
MA50
24.403
Buy
MA100
23.862
Buy
MA200
22.555
Buy

Institutional Confidence

Currency: USD Updated2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 111.34%, representing a quarter-over-quarter decrease of 4.65%. The largest institutional shareholder is Ron Baron, holding a total of 1.89M shares, representing 3.81% of shares outstanding, with 3.75% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Conestoga Capital Advisors, LLC
8.19M
+1.32%
Neuberger Berman, LLC
4.60M
-0.82%
T. Rowe Price Investment Management, Inc.
3.74M
+13.30%
TimesSquare Capital Management, LLC
3.36M
+2.14%
Artisan Partners Limited Partnership
2.28M
-3.28%
Thrivent Asset Management, LLC
2.78M
-0.30%
Baron Capital Management, Inc.
Star Investors
1.85M
+1.67%
ArrowMark Colorado Holdings, LLC
815.00K
+234.31%
Champlain Investment Partners, LLC
770.85K
--
1
2

Risk Assessment

Currency: USD Updated2025-09-17

The company’s current risk assessment score is 5.66, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.66
Change
0
Beta vs S&P 500 index
0.57
VaR
--
240-Day Maximum Drawdown
+24.89%
240-Day Volatility
+63.01%
Return
Best Daily Return
60 days
+10.00%
120 days
+11.15%
5 years
--
Worst Daily Return
60 days
-9.73%
120 days
-9.73%
5 years
--
Sharpe Ratio
60 days
+1.44
120 days
+1.27
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+24.89%
3 years
+52.30%
5 years
--
Return-to-Drawdown Ratio
240 days
+1.28
3 years
+0.46
5 years
--
Skewness
240 days
+0.57
3 years
-0.23
5 years
--
Volatility
Realised Volatility
240 days
+63.01%
5 years
--
Standardised True Range
240 days
+4.49%
5 years
--
Downside Risk-Adjusted Return
120 days
+225.80%
240 days
+225.80%
Maximum Daily Upside Volatility
60 days
+42.02%
Maximum Daily Downside Volatility
60 days
+34.83%
Liquidity
Average Turnover Rate
60 days
+0.12%
120 days
+0.12%
5 years
--
Turnover Deviation
20 days
-17.17%
60 days
-19.88%
120 days
-21.32%

Peer Comparison

Healthcare Equipment & Supplies
Stevanato Group SpA
Stevanato Group SpA
STVN
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
7.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI